Document is current
Any future updates will be listed below
-
Authors
Haulrig, Morten B. https://orcid.org/0000-0002-5553-3213
Kabatnik, Sonja https://orcid.org/0000-0001-6524-6982
Skov, Lone https://orcid.org/0000-0002-4784-9680
Løvendorf, Marianne B. https://orcid.org/0000-0002-7361-5845
Dyring-Andersen, Beatrice https://orcid.org/0000-0002-3012-2645
-
Funding
Funding for this research was provided by:
Kongelig Hofbuntmager Aage Bangs Fond
Novo Nordisk Fonden (NNF21OC0066694)
Herlev and Gentofte Research council
Kong Christian den Tiendes Fond
Else og Mogens Wedell Wedellsborgs Fond
LEO Fondet (LF-ST-21-500002)
- License Information
-
More Information
Article History
Received: 10 February 2026
Accepted: 24 March 2026
First Online: 17 April 2026
Change Date: 5 May 2026
Change Type: Update
Change Details: Equal contribution updated.
Declarations
:
: Lone Skov has been an advisor, investigator, and speaker for Abbvie, Eli Lilly, Novartis, Sanofi, LEO Pharma, BMS, UCB, Incyte, Stada, Takeda, Pfizer and Almirall, unrelated to the submitted work. Lone Skov reports nonfinancial support from grants from Almirall, Novartis, Janssen, BMS, Sanofi and UCB. Morten Bahrt Haulrig, Sonja Kabatnik, Beatrice Dyring-Andersen and Marianne B. Løvendorf have nothing to disclose.
: The study was approved by the Ethics Committee of the Danish Capital Region (H-19036270) and the Danish Data Protection Agency, and it followed the principles of the Declaration of Helsinki II.
